News
NVS
145.46
+1.32%
1.89
Catalyst Watch: Jobs report, Trump AI talks, and ticking fee time for Paramount
Seeking Alpha · 2d ago
Nuvectis’ In-Licensed Cancer Drug Earned Breakthrough Designation in China, and It’s Not Even Their Lead Asset
TipRanks · 3d ago
FDA commissioner nominee Overton rebuffs questions about Trump medical claims
Seeking Alpha · 3d ago
Buy Rating Reiterated on Novartis as Diversified Pipeline Supports Medium-Term Growth; CHF 150 Price Target Unchanged
TipRanks · 3d ago
A Federal Judge In Manhattan Ruled For Novartis On Wednesday Against Allegations That It Misused One Of Its Patents To Maintain Its Exclusivity On Its Blockbuster Heart-Failure Drug Entresto
Benzinga · 4d ago
Ionis Delivers Positive Late-Stage Results for Two Partnered Drugs
NASDAQ · 4d ago
HSBC Remains a Buy on Novartis AG (NOVN)
TipRanks · 5d ago
Celldex Prepares For 2027 FDA Submission for Chronic Skin Disease
Benzinga · 5d ago
Lantheus gains approval of Bravnesta, generic competitor to Lutathera
Seeking Alpha · 5d ago
BoomRay Pharma, Novartis Ink Radioligand Therapy Licensing Deal Worth Up To $900 Mln
NASDAQ · 6d ago
Goldman Sachs Keeps Their Sell Rating on Novartis AG (NOVN)
TipRanks · 6d ago
Cue Biopharma: Initiating 'Buy' Based On CUE-221 Trial Win CSU With Novel Dual MOA
Seeking Alpha · 6d ago
Cue Biopharma plummets on phase 2 data for chronic spontaneous urticaria asset
Seeking Alpha · 6d ago
Trump Trade: U.S. announces deal with Denmark over Greenland’s security
TipRanks · 6d ago
Weekly Report: what happened at NVS last week (0914-0918)?
Weekly Report · 09/21 09:33
Novartis' Pipeline In Focus After A Series Of Clinical Setbacks
NASDAQ · 09/21 09:12
Dated September 17, CHMP Recommends EU Label Expansion For Novartis' Cosentyx In Polymyalgia Rheumatica After Inadequate Glucocorticoid Response Or Relapse During Taper
Benzinga · 09/18 15:08
Novartis announces positive CHMP opinion for Cosentyx
TipRanks · 09/18 15:00
U.S. weighs allowing most pharma licensing deals with China, Reuters says
TipRanks · 09/18 14:40
5 Undervalued Oncology Stocks Wall Street Is Overlooking
Seeking Alpha · 09/18 13:22
More
Webull provides a variety of real-time NVS stock news. You can receive the latest news about Novartis through multiple platforms. This information may help you make smarter investment decisions.
About NVS
Novartis AG is a Switzerland-based pharmaceutical company. The Company develops, manufactures, and markets branded and generic prescription drugs, active pharmaceutical ingredients (APIs), biosimilars and ophthalmic products. The Company uses science and digital technologies for treatments in the disease areas of immunology, dermatology, cancer, ophthalmology, neuroscience, respiratory, cardiovascular, renal and metabolism. The business activities of the Company are divided into two segments: Innovative Medicines, which includes innovative patent-protected prescription medicines for blood pressure, cancer and other ailments, and Sandoz, which includes generic pharmaceuticals and biosimilars.